Newmeco, a subsidiary of Medytox, has received approval from the Azerbaijan Ministry of Health for its botulinum toxin product, Newlux. The company plans to accelerate its strategy for expanding into neighboring countries, leveraging the growing demand for medical tourism in the region.
On June 30, Newmeco announced that it had secured the necessary product registration for Newlux in Azerbaijan.
Azerbaijan's medical tourism industry is rapidly expanding, particularly in the capital city of Baku, leading to increased demand for cosmetic procedures. Newmeco aims to utilize the existing distribution network and partnerships established by Medytox to quickly establish a foothold in the market.
Medytox previously launched its botulinum toxin product, Meditoxin (export name Qunox), in 2019, followed by four types of hyaluronic acid fillers, Newramis, in 2020, laying the groundwork for its market presence. Newmeco plans to pursue additional product registrations in neighboring countries, furthering its international market expansion.
A Newmeco representative stated, "This approval has secured a strategic base for entering neighboring countries. We will enhance local partnerships and implement tailored strategies for each country to increase our global market share."
Newlux is a botulinum toxin product developed by Newmeco, notable for being the first in its category to use a non-animal-based medium in its manufacturing process, enhancing safety. Additionally, it minimizes chemical processing to reduce the denaturation of effective neurotoxin proteins.
Emerging markets are viewed as having significant long-term growth potential due to rising incomes and access to affordable products. The company has been expanding globally since 2024, starting with Peru and continuing into Thailand, Georgia, and Bolivia.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.